Raheel, Kausar
See, Qi Rui
Munday, Veronica
Fakhroo, Basma
Ivanenko, Olga
Salvatelli, Marcello Luigi
Mutti, Carlotta
Goadsby, Peter J.
Delogu, Alessio
Naismith, Sharon L.
Holland, Phil
Parrino, Liborio
Chaudhuri, K. Ray
Rosenzweig, Ivana
Article History
Accepted: 2 July 2024
First Online: 20 July 2024
Declarations
:
: The authors declare the following competing financial interest(s): grants from Celgene and Kallyope, Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer (P.J.G); consulting fees from Aeon Biopharma, Abbvie, Amgen, CoolTech LLC, Epalex, Eli Lilly, Sanofi, Gerson Lehrman Group, Guidepoint, Linpharma, Lundbeck, Novartis, Pfizer, Vector Metric, SAI Med Partners, Satsuma, Shiratronics and Teva Pharmaceuticals (P.J.G). Grants from the Medical Research Council (MRC) (MR/P006264/1 and MR/N013700/1, PhD studentship for E.C.S and grant from Eli Lilly and Company (Eli Lilly Research Award Program (LRAP)) (P.H.). The advisory board for AbbVie, UCB, GKC, Bial Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma, receives grants from Bial, Britannia Pharmaceuticals, AbbVie, UCB, GKC, EU Horizon 2020, Parkinson's UK, NIHR, Parkinson’s Foundation, Wellcome Trust, Kirby Laing Foundation, MRC, MDS (MDS NMS Project), royalties or licenses from Oxford (book), Cambridge publishers (book), MAPI institute (KPPS, PDSS 2) and expert testimony from GMC, NICE, NIHR (K.R.C). Authors K.R., S.Q.R, V.M., B.F., O.I., M.L.S., C.M., A.D., S.L.N., L.P., I.R. have no competing interests.